RxDoctor Payments Data

Chebel Khalil, MD

Nephrology · Cincinnati, OHNPI 1841400645

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $47,975 of the $71,778 with a category attached, or 66.8%. Amgen accounts for 65.6% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $40,270, more than ten times the $90 reported in 2019. Among nephrology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$71,778in general payments, 2019–2025

Across 223 payments — averaging $321.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$47K
  • Travere Therapeutics, Inc.$22K
  • Merit Medical Systems Inc$778
  • AstraZeneca$615
  • Boehringer Ingelheim$421
  • Calliditas Therapeutics US Inc.$169
  • plus $736 from 13 others

What the payments were for

  • Consulting fees$12,70018%
  • Speaking & faculty fees$47,97567%
  • Travel & lodging$5,0447%
  • Food & beverage$5,8948%
  • Education$1650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,778 in reported general payments places this provider in the 95th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$125,759
Medicare patients
392
Services billed
1,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$12,502
Sevelamer Carbonate34$5,425
Nifedipine ErNifedipine135$4,364
Calcitriol288$3,466
Calcium Acetate25$2,357
Clonidine21$2,085
Torsemide60$1,633
Doxazosin Mesylate67$1,223
Allopurinol149$1,200
Hydralazine Hcl73$1,098
Potassium Citrate ErPotassium Citrate11$976
Metoprolol Succinate51$813
Losartan Potassium82$674
Valsartan20$668
Metoprolol Tartrate120$637

Paid to pharmacies, not to this prescriber.

Other nephrology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →